polymerase, we analyzed by nuclear magnetic resonance spectroscopy the structure and dynamics of a DNA duplex containing cidofovir and an isosequential control DNA. The oligonucleotide was synthesized from the 5'-to-3' end by adapting the solid-phase procedure described by Birkus et al. for (S)-HPMPA oligonucleotides [Birkus et al., 2004, Antivir. Chem. Chemother. 15, 23–33]. Reversed 5' phosphoramidites were introduced into the oligonucleotide chain using phosphoramidite chemistry. The appropriately protected CDV monomer was prepared by a multistep synthesis starting from N<sup>4</sup>-benzoylcytosine and (S)-glycidyl trityl ether and was added to the oligo using the phosphotriester condensation method. From the NMR it is clear that the cidofovir containing DNA is distorted in structure. No imino-imino contacts were found in the cidofovir containing DNA, implying that the base pairing dynamics are much higher than that of the control DNA. Further, the imino protons of the neighboring nucleobases near the cidofovir moiety exchange more easily than those in control DNA. These experiments suggest there is a bulge near to the location of cidofovir in the DNA core. These results should provide further details about the mechanisms by which CDV inhibits vaccinia polymerase activity.

doi:10.1016/j.antiviral.2010.02.427

#### 118

# Inhibition of Calicivirus Replication in Mammalian Cells by RNAI

Mirko Bergmann, Jacques Rohayem\*

Institute of Virology, Dresden University of Technology, Germany

E-mail address: jacques.rohayem@tu-dresden.de (J. Rohayem).

Caliciviruses are non-enveloped viruses with a single stranded positive orientated RNA genome. They include human pathogenic (norovirus and sapovirus) and non-human pathogenic genera (vesivirus and lagovirus). Because of the increasing number of human infections and the absence of possibilities for vaccination as well as an antiviral therapy, it is of interest to develop antiviral strategies against human pathogenic caliciviruses. The objective of our study is to use the feline calicivirus in order to proof the concept of siRNA application as a new approach to control calicivirus infections. In contrast to the vast majority of caliciviruses that so far remain non-cultivable, the feline calicivirus (FCV, vesivirus) can be passed in CRFK-monolayers and is therefore used as a cell model for antiviral research. Our investigations include two different FCV strains (FCV-DD06 [GB Acc. No. DQ424892] and FCV-2024 [GB Acc. No. AF479590]). We have observed antiviral effects on several aspects of viral replication like reduction of infectious particles, the level of viral genomic RNA and inhibition of viral translation. siRNA-molecules targeting conserved genomic sequences lead either to a complete reduction of the viral titer or to a decrease of virions by two log scales (1.95E+05PfU/ml vs. a positive control of 4.08E + 07 PfU/ml). Similarly, viral genomic RNA level was decreased by about 30–50% in comparison to a positive control. Analysis by western blot reveals no detectable signal for structural and non-structural viral proteins after siRNA application. Quantification of the antiviral activity was performed with a cell proliferation assay resulting in an EC50 value of 0.69  $\mu$ M. Our data underlines the potential of the siRNA approach as a novel strategy to control calicivirus infection.

doi:10.1016/j.antiviral.2010.02.428

119

Withdrawn

doi:10.1016/j.antiviral.2010.02.429

#### 120

# **Developing Capsid Inhibitor V-073 for Poliovirus**

Marc Collett\*, Jeffrey Hincks

ViroDefense Inc., Rockville, USA

V-073, an enterovirus capsid inhibitor, has potent broad spectrum of anti-poliovirus activity *in vitro*. The compound has exhibited desirable attributes in nonclinical pharmacologic and toxicologic studies, which support the continued advancement of V-073 to first-in-human clinical studies. These attributes will be reviewed, as will the rationale for additional poliovirus antiviral development.

# doi:10.1016/j.antiviral.2010.02.430

#### 121

### **Addition Antiflogistic to Viral Inhibitor**

G. Danilenko<sup>1,\*</sup>, S. Rybalko<sup>2</sup>, T. Bukhtiarova<sup>3</sup>, V. Danilenko<sup>3</sup>, S. Guzhova<sup>1</sup>, V. Lozitsky<sup>4</sup>

<sup>1</sup> Institute of Organic Chemistry, Kyiv, Ukraine; <sup>2</sup> Institute of Epidemiology and Infectional Diseases, Kyiv, Ukraine; <sup>3</sup> Institute of Pharmacology and Toxicology, Kyiv, Ukraine; <sup>4</sup> Ukrainian Mechnikov Research Anti-Plague Institute, Odesa, Ukraine

Earlier we have been shown new viral inhibitors may be found among compounds with reliable anti-inflammatory properties. It may be supposed inflammatory and virus inhibitors influence at two independent parts of viral reproduction and therefore combine action of antiflogistic and antiviral remedies may be more potent in comparison with activity level of antiflogistic or virus inhibitor per se. These results present in table. Previous result seems to support this conclusion. Acyclovir is more potent than indometacin but a mixture is active as (I) ever in diminished dose. I + II overestimated as I and II if virus is added after I + II.

Comp		HSV-1, initial titer 4 IgID50, compounds are added in 24 virus infection		ıfter	HSV-1, initial titer 5 IgID50, compounds are added in 24 h before virus infection		
		Acyclovir (I)	Indometacin (II)	I+II (mol:mol)	I	II	I+II (mol:mol)
Dose mi Titer IgI	0,	50 1	50 2	25 1	50 1	50 3	37.5 <1.0

doi:10.1016/j.antiviral.2010.02.431

#### 122

# Unsymmetrical CADA Analogs as Novel Down-modulators of the CD4 Receptor

Violeta Demillo <sup>1,\*</sup>, Kurt Vermeire <sup>2</sup>, Dominique Schols <sup>2</sup>, Thomas Bell <sup>1</sup>

<sup>1</sup> Department of Chemistry, University of Nevada, Reno, USA; <sup>2</sup> Rega Institute for Medical Research, Department of Microbiology and Immunology, Katholieke Universiteit Leuven, Leuven, Belgium

Cyclotriazadisulfonamide (CADA) inhibits the entry of HIV into CD4<sup>+</sup> target cells. This effect is due to the compound's ability to down-modulate the expression of the primary cellular receptor for HIV, CD4. Structural modifications of CADA have been made to increase potency, reduce toxicity, and improve physical properties. For 19 CADA analogs, a strict correlation between the CD4 down-modulating and antiviral activities has been observed. The interest